SML3682
ST2825
≥98% (HPLC), MyD88 dimerization inhibitor, powder
别名:
(2R,4′R,8′aR)-1-[2-[4-[[2-(2,4-Dichlorophenoxy)acetyl]amino]phenyl]acetyl]tetrahydro-6′-oxo-spiro[pyrrolidine-2,7′(6′H)-[2H]pyrrolo[2,1-b][1,3]thiazine]-4′-carboxamide, PAM4-SP19-Beta8-NH2, ST 2825, ST-2825
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C27H28Cl2N4O5S
化学文摘社编号:
分子量:
591.51
UNSPSC Code:
51111800
NACRES:
NA.21
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
产品名称
ST2825, ≥98% (HPLC)
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Biochem/physiol Actions
Orally active peptidomimetic MyD88 homodimerization inhibitor with in vitro and in vivo efficacy against IL-1R and TLR9-dependent processes.
ST2825 is an orally active peptidomimetic of a heptapeptide structure in the MyD88 TIR BB-loop. ST2825 prevents IL-1beta-mediated activation of NF-kappaB by blocking MyD88 homodimerization and thereby the recruitment of IL-1 receptor-associated kinases IRAK1/4. ST2825 at 10 µg/mL completely suppresses 2.5 µg/mL TLR9 ligand ODN 2006-induced B-cell plasma cell differentation and antibodies production from PBMCs. ST2825 inhibits IL-1β-induced IL-6 production in mice (100 & 200 mg/kg p.o. prior to 20 µg/kg IL-1β i.p.) and protects against left ventricular (LV) dilatation and hypertrophy (25 mg/kg/day i.p.) in a murine model of nonreperfused acute myocardial infarction (AMI) in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable